Join to View Full Profile
1365 Clifton Rd NEBldg CAtlanta, GA 30322
Phone+1 404-778-0519
Dr. Cohen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2010 - 2013- Ohio State University HospitalResidency, Internal Medicine, 2007 - 2010
University of Florida College of MedicineClass of 2007
Certifications & Licensure
GA State Medical License 2013 - 2026
OH State Medical License 2007 - 2015
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2014-2015, 2017
- CMS Meaningful Use Stage 1 Certification P2 Sentinel, Cerner Corporation, 2014-2015, 2017
- CMS Meaningful Use Stage 1 Certification Clinical Data Warehouse Meaningful Use, Emory Healthcare, 2014-2015, 2017
Clinical Trials
- Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2012 Feb 09
- Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2016 Jan 01
- Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission Start of enrollment: 2016 Mar 01
Publications & Presentations
PubMed
- 1 citationsOutcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.John S Wang, Brandon L Ellsworth, Megan Melody, Narendranath Epperla, Deborah Stephens
Blood Advances. 2026-02-10 - 1 citationsOutcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.Megan Melody, Natalie Grover, Stephanie Franco, Jason Romancik, Matthew Cortese
Blood Advances. 2026-01-13 - A new standard for relapsed or refractory follicular lymphoma.Reut Harel, Jonathon B Cohen
Lancet. 2026-01-10
Journal Articles
- Intrathecal Central Nervous System Prophylaxis in Patients with Diffuse Large B-cell Lymphoma at an Academic Healthcare SystemJonathon Cohen, MD, Clinical Lymphoma, Myeloma, & Leukemia
Abstracts/Posters
- Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin LymphomaJonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell LymphomaJonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...Jonathon B. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE040461st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Expert Perspectives on the Role of BTK Inhibitors in CLL61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Authored Content
- ASH 2018: Novel Therapies for Relapsed/Refractory Aggressive LymphomasDecember 2018
- ASH 2018: Novel Therapies for Relapsed/Refractory Aggressive LymphomasDecember 2018
Press Mentions
Mantle Cell Lymphoma: Optimizing Current TherapiesOctober 28th, 2022- Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma PatientsNovember 29th, 2021
- CAR T-cell Therapy: Is It Right for You?July 8th, 2021
Grant Support
- Increasing Participation in NCI-Funded Clinical Trials at Winship Cancer InstituteEMORY UNIVERSITY2023–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
